<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04874961</url>
  </required_header>
  <id_info>
    <org_study_id>Olijfstudie 2021</org_study_id>
    <nct_id>NCT04874961</nct_id>
  </id_info>
  <brief_title>Olive Polyphenols in Cardiovascular Prevention.</brief_title>
  <official_title>Olive Polyphenols in Cardiovascular Prevention: Efficacy and Tolerability of a Commercially Available Standardized Olive Extract (Tensiofytol) as Compared to a Combination Preparation (Cholesfytol NG) and Placebo in Metabolic Syndrome: a RDBPC Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nina Hermans</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universiteit Antwerpen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate whether the use of a commercially available standardized&#xD;
      olive extract (Tensiofytol) and a commercially available combination preparation (Cholesfytol&#xD;
      NG) by individuals with metabolic syndrome&#xD;
&#xD;
        1. Leads to a clinically relevant reduction of blood pressure on the short term,&#xD;
&#xD;
        2. Leads to a clinically relevant reduction of cholesterol levels, especially LDL,&#xD;
&#xD;
        3. Leads to a change in oxidative stress biomarkers.&#xD;
&#xD;
      Participants will be stratified by sex and menopausal status before randomization to one of&#xD;
      the three treatments for 8 weeks:&#xD;
&#xD;
        -  Tensiofytol: 100 mg oleuropeïne and 20 mg hydroxytyrosol per day&#xD;
&#xD;
        -  Cholesfytol NG: 2.9 mg monacoline K and 10 mg hydroxytyrosol per day&#xD;
&#xD;
        -  Placebo&#xD;
&#xD;
      All treatments have an identical shape and color and should be used in the same way (oral&#xD;
      intake; 3 capsules/day during dinner). No dietary instructions are given and participants are&#xD;
      asked not to change their dietary habits, nor to start other therapies (medication,&#xD;
      supplements, slimming diets, extra physical activity, etc.) during their study period.&#xD;
      Standardized questionnaires are used to obtain information on demographics, dietary habits&#xD;
      and side effects. At baseline and after 8 weeks, 27 ml blood is drawn for various biological&#xD;
      analyses, and blood pressure, BMI and waist circumference are measured.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline Blood Pressure at 8 weeks</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>average of 3 measurements during 15 minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Blood Pressure at 4 weeks</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>average of 3 measurements during 15 minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline LDL cholesterol level at 8 weeks</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline HDL cholesterol level at 8 weeks</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline total cholesterol level at 8 weeks</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline triglycerides level at 8 weeks</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline glucose level at 8 weeks</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline insuline level at 8 weeks</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>Required to correctly interpret glucose levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Apo A1 level at 8 weeks</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Apo B level at 8 weeks</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline homocysteine level at 8 weeks</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline lipoprotein A (LP(a)) level at 8 weeks</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline hs-CRP level at 8 weeks</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline creatinine level at 8 weeks</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>Required to correctly interpret HbAc1 levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline HbA1c level at 8 weeks</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline hemoglobine level at 8 weeks</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>Required to correctly interpret HbAc1 levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline OxLDL level at 8 weeks</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline gluathion (GSH) level at 8 weeks</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline malondialdehyde (MDA) level at 8 weeks</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline creatine kinase (CK) level at 8 weeks</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Body Mass Index (BMI) at 8 weeks</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>weight and height will be combined to report BMI in kg/m^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline waist circumference at 8 weeks</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of side effects (+ their burden) as reported in the final questionnaire</measure>
    <time_frame>8 weeks</time_frame>
    <description>Unvalidated but standardized questionnaire on typical statin-related side effects</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>High Blood Pressure</condition>
  <condition>High Cholesterol</condition>
  <condition>Dyslipidemias</condition>
  <condition>High Blood Sugar</condition>
  <arm_group>
    <arm_group_label>Standardized olive extract (Tensiofytol)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 capsules/day during dinner Per day: 334 mg olive leave dry extract and 106 mg olive fruit dry extract (Olea europaea), equivalent to 100 mg oleuropeïne and 20 mg hydroxytyrosol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination preparation (Cholesfytol NG)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 capsules/day during dinner&#xD;
Per day:&#xD;
67.2 mg red yeast rice powder (Monascus purpureus; equivalent to 2.9 mg monacoline K)&#xD;
1000 mg amla dry extract (Phyllanthus emblica)&#xD;
100 mg walnut leave dry extract (Juglans regia)&#xD;
50 mg olive dry extract (Olea europaea; equivalent to 10 mg hydroxytyrosol)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 capsules/day during dinner</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Tensiofytol</intervention_name>
    <description>standardized olive extract</description>
    <arm_group_label>Standardized olive extract (Tensiofytol)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cholesfytol NG</intervention_name>
    <description>combination preparation</description>
    <arm_group_label>Combination preparation (Cholesfytol NG)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>contains excipients only</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  LDL cholesterol level ≥ 160 mg/dL (corrected for LP(a))&#xD;
&#xD;
          -  Metabolic syndrome as defined by ATPIII-criteria: at least 3 of the following 5&#xD;
             criteria, but certainly high blood pressure:&#xD;
&#xD;
               1. Blood pressure ≥ 130/85 mg Hg or blood pressure medication (arterial&#xD;
                  hypertension)&#xD;
&#xD;
               2. Waist circumference &gt; 102 cm for men or &gt; 88 cm for women&#xD;
&#xD;
               3. Triglycerides ≥ 150mg/dL&#xD;
&#xD;
               4. HDL cholesterol &lt; 40mg/dL for men or &lt; 50mg/dL for women&#xD;
&#xD;
               5. Fasting glucose ≥ 110 mg/dL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt;18 jaar&#xD;
&#xD;
          -  &gt;70 jaar&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Use of nutritional supplemenrs&#xD;
&#xD;
          -  Use of cholesterol lowering medication or other medication except for blood pressure&#xD;
             medication&#xD;
&#xD;
          -  Triglycerides &gt; 400 mg/dL&#xD;
&#xD;
          -  &gt; 2 alcoholic consumptions/day&#xD;
&#xD;
          -  Chronic illness (e.g. diabetes, atherosclerosis, reumatoid arthritis)&#xD;
&#xD;
          -  Acute infection&#xD;
&#xD;
          -  Current pregnancy or pregnancy wish during the study period&#xD;
&#xD;
          -  Breast feeding&#xD;
&#xD;
        When nutritional supplements were used regularly, participation is allowed after a 10-day&#xD;
        wash out period. Subjects who used cholesterol lowering medication or nutritional&#xD;
        supplements with red yeast rice, can participate after a 6-week wash out.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Annelies Verlaet, PhD</last_name>
    <phone>003232652706</phone>
    <email>annelies.verlaet@uantwerpen.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nina Hermans, Prof.</last_name>
    <phone>003232652732</phone>
    <email>nina.hermans@uantwerpen.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UAntwerp, NatuRA</name>
      <address>
        <city>Wilrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Hermans, Prof</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 27, 2021</study_first_submitted>
  <study_first_submitted_qc>April 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universiteit Antwerpen</investigator_affiliation>
    <investigator_full_name>Nina Hermans</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

